News
ANAB
23.12
+2.21%
0.50
AnaptysBio (NASDAQ:ANAB) shareholders are up 11% this past week, but still in the red over the last three years
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But that...
Simply Wall St. · 1d ago
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indicatio...
GlobeNewswire · 06/02 20:05
Short Volatility Alert: AnaptysBio, Inc.
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish.
Benzinga · 05/26 15:12
AnaptysBio's Return On Capital Employed Insights
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.
Benzinga · 05/24 13:48
Downgrade: Here's How Analysts See AnaptysBio, Inc. (NASDAQ:ANAB) Performing In The Near Term
One thing we could say about the analysts on AnaptysBio, Inc. ( NASDAQ:ANAB ) - they aren't optimistic, having just...
Simply Wall St. · 05/10 10:09
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:55
AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M
AnaptysBio press release (NASDAQ:ANAB): Q1 GAAP EPS of -$1.31 misses by $0.32. Revenue of $0.97M (-91.4% Y/Y) misses by $4.08M. Shares -1.6% AH. Top-line data from the ongoing imsidolimab (anti-IL-36R
Seekingalpha · 05/04 21:41
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 04/28 12:52
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
Benzinga · 04/28 12:48
BRIEF-Anaptysbio Announces Positive Anb032 (Anti-Btla Agonist) Top-Line Phase 1 Data And Provides Pipeline Updates
reuters.com · 04/27 20:34
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement of ANB032 into subsequent patient trialsANB032 IND filing in an...
GlobeNewswire · 04/27 20:15
AnaptysBio, Inc. (ANAB) Soars 6.2%: Is Further Upside Left in the Stock?
AnaptysBio, Inc. (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks · 04/26 11:05
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 03/22 12:31
AnaptysBio names interim CEO as Hamza Suria steps down
AnaptysBio (NASDAQ:ANAB) said it has appointed Daniel Faga as its interim President and CEO, effective immediately. The transition comes as Hamza Suria stepped down from his role as AnaptysBio's President and CEO and
Seekingalpha · 03/21 20:29
BRIEF-AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
reuters.com · 03/21 20:23
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotec...
GlobeNewswire · 03/21 20:15
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
AnaptysBio's (ANAB) phase II study evaluating imsidolimab for treating moderate-to-severe acne, fails to show improvement over placebo in top-line primary or secondary endpoints. Shares down.
Zacks · 03/15 15:35
Hot Stocks: AMC invests in gold mine; DOLE earnings; ZM upgrade; ANAB clinical data
Meme-stock darling AMC Entertainment (NYSE:AMC) received attention in Tuesday's pre-market trading after announcing a surprise investment. The movie theater chain said it was buying a sizable stake in a Nevada-based
Seekingalpha · 03/15 12:38
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne 
Benzinga · 03/15 12:07
BRIEF-AnaptysBio Reports Imsidolimab Acorn Phase 2 Clinical Trial Data In Moderate-To-Severe Acne
reuters.com · 03/14 20:43
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company developing immunology therapeutic product. The Company is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. It develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.